| Project ID: | MCC-002 |
| Sample ID: | MCC-002-01-1A |
| Submitted by: | NCBI (GEO) |
| Country: | USA |
| BioProject | PRJNA484204 |
| Sample name | NA |
| SRA accession: | SRP157915 |
| SRS accession: | SRS3668880 |
| SRX accession: | SRX4551785 |
| SRR accession: | SRR7692288 |
| GEO accession: | GSE118056 |
| Cancer type: | Merkel Cell Carcinoma |
| Cancer type abbreviation: | MCC |
| Primary site: | Skin |
| Tissue: | Skin |
| Tumor grade: | IIIB |
| Tumor status: | Metastatic |
| Donor age: | 59 |
| Donor gender: | Male |
| Treatment: | Treated with MCPyV-specific CD8+ T cells and checkpoint inhibition, this time with T cells restricted to HLA-A2 and avelumab (anti-PD-L1) as checkpoint inhibition. |
| Other metadata: | NA |
| Project title: | scRNAseq reveals mechanisms of Merkel cell carcinoma acquired immunotherapy resistance |
| Project abstract: | PBMC and tumor specimen from a Merkel cell carcinoma tumor at time of immunotherapy resistance Overall design: PBMC and tumor specimen from a human patient with MCPyV associated Merkel cell carcinoma treated with T cell therapy and avelumab (anti-PD-L1), from a time point of late immunotherapy resistance; validation patient. |
| Construction protocol: | PBMC were isolated with standard FICOLL, tumor tissues were digested in RPMI with DNAse, Collagenase, and hyaluronidase, strained and frozen. All samples were thawed on same day and immediately processed 10X Genomics 5' Chromium single cell RNA sequencing Gene expression per manufacturer's instructions. |
| Protocol: | 10X Genomics |
| Instrument: | Illumina NovaSeq 6000 |
| Strategy: | RNA-Seq |
| Layout: | PAIRED |
| Publications: | K.G. Paulson et al., Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature Communications, 2018, 9(1): 3868 |
